作者
I Ikonomidis, E Michalopoulou, G Pavlidis, V Prentza, K Katogiannis, G Kostelli, D Vythoulkas, A Kountouri, E Korakas, L Pliouta, J Thymis, V Lambadiari
发表日期
2023/11
期刊
European Heart Journal
卷号
44
期号
Supplement_2
页码范围
ehad655. 2560
出版商
Oxford University Press
简介
Background/Introduction
Patients with type-2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) present increase risk of cardiovascular disease. Sodium-glucose contrasporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to significantly reduce the risk of cardiovascular complications.
Purpose
The aim of the study was to investigate the effect of treatment with SGLT-2i or GLP-1RA on vascular function and liver steatosis and fibrosis in patients with T2DM and NAFLD.
Methods
Thirty patients with T2DM and NAFLD (mean age: 57±11 years) were randomized to receive SGLT-2i (dapagliflozin; n=15) or GLP-1RA (dulaglutide; n=15). At baseline and at 6 months post-treatment, we measured: (1) Perfused boundary region (PBR) of the sublingual microvessels with a diameter 5-25μm using …
学术搜索中的文章
I Ikonomidis, E Michalopoulou, G Pavlidis, V Prentza… - European Heart Journal, 2023